Spyre Therapeutics raises ~$463.5M in underwritten public offering of 7.475M shares at $62.00/share

Spyre Therapeutics, Inc.

Gross proceeds of ~$463.5M from 7.475M shares including full exercise of over-allotment option at $62.00/share.
Proceeds to fund IBD and rheumatic disease programs, including preclinical, clinical trials, manufacturing, and Phase 3 readiness.
Underwriting agreement with Jefferies, Goldman Sachs, Evercore, and Guggenheim Securities as representatives.
Offering closed on April 16, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Spyre Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC, as the representatives of the underwriters valued at approximately $463.5 million (effective 2026-04-14).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC, as the representatives of the underwriters
Value: approximately $463.5 million
Effective: 2026-04-14

Exact text from the filing

The Underwriting Agreement contains customary representations and warranties, agreements and obligations, conditions to closing and termination provisions.

View on SEC.gov

Browse all material agreements →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-025508

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.